Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: John Zwiener who wrote (751)	12/21/1997 4:50:00 PM
From: Cisco	Read Replies (1) \| Respond to of 1894

John, Just for clarification, are you talking about the insider trading on CYTC and their article in OB/GYN supporting ThinPrep's FDA approval? I just want to make sure I am responding to right assumptions. Cisco

To: John Zwiener who wrote (751)	12/22/1997 12:57:00 AM
From: Cisco	Respond to of 1894

John, (First of three posts) All I can tell you John is why I continue to hold several thousand shares of ACMI. Much of the following information is taken directly from SEC filings and information publically disseminated by AccuMed. I. It is a multi-faceted company with leading edge products continuing to be rolled out. a. Microbiology Divison 1. AlamarBlue: a non-toxic cell growth and cytotoxicity indicator dye. 2. AccuMed Sensititre System: a fully automated bacterial susceptibility and identification system with emphasis on flexibility, true MIC panels, automated inoculation, automated reading, cost-effective, and rapid organism identification with fully automated reports. 3. AccuMed ESP Culture System II: provides non-invasive continuous monitoring of cultures with walkaway automation for blood culture, body fluid testing, and mycobacteria testing. They recently announced that they are first to be cleared by the FDA for use with DNA probes for more rapid mycobacteria identification. 4. AccuMed AccuZone: a fully automated Kirby-Bauer reader is being launched first quarter of 1998. 5. Flourotone 48: another diagnostic microbiolocial test panel with an automated reader in development. 6. RISE & PZA Kit: susceptibility tests for Mycobacterium tuberculosis currently before the FDA waiting for clearance.

To: John Zwiener who wrote (751)	12/22/1997 1:01:00 AM
From: Cisco	Respond to of 1894

John, (Second of three posts) b. Cytopathology Divison 1. AcCell 2000: an interactive computer-controlled slide handling and precision microscopy workstation supported with comprehensive data management capabilities. The AcCell can be linked to the gynecologist's office and to the laboratory's internal information system in order to provide computerized support, from time of entering patient information when the specimen is taken through the time of generating reports at the laboratory and doctor's office and finally to billing of the patient or payor. 2. AcCell 2001: an AcCell workstation with an automated cassette slide loading and unloading system which handles upto 30 slides per cassette. Several workstations can be networked together within a single laboratory. 3. MacroVision: a proprietary image enhancement system which can be attached to the AcCell platform. 4. The company is currently developing a proprietary telepathology software which would enable the AcCell workstation to be operated remotely using the MacroVision product. 5. TracCell 2000: a pre-screening, mapping and slide handling product designed to identify and create a computerized map of vacant space, blood, mucus, and other non-clinically relevant material as well as determining if samples are properly stained and has sufficent material to be statistically significant. The TracCell 2000 is designed to be used before the slide is reviewed using the AcCell 2001. A single TracCell is designed to support up to five AcCell 2001 instruments. 6. TracCell 2500: a second generation TracCell which will eliminate not only empty space, debris and other material eliminated by the TracCell 2000, but will also eliminate certain normal cellular material. Amendment is to be filed with the FDA for approval during first quarter of 1998. 7. Oncometrics' research is currently developing an instrument capable of isolating a small variation in cell nucleus DNA, which assists the cytotechnologist in detecting lung cancer in early stage of development and possibly even in a precancerous state. Oncometrics believes that its technology may be potentially applied to other types of cancer, such as cervical cancer. Several prototypes are currently being tested by scientists and cancer research institiutions.

To: John Zwiener who wrote (751)	12/22/1997 2:50:00 AM
From: Cisco	Respond to of 1894

John, (third of three) II. AccuMed has demonstrated increased productivity and improved screening of monolayer slides. III. ACMI has an extremely low price to sales ratio. IV. ACMI market cap is currently less than what analysts are projecting as sales revenues in 1998. V. Analysts have ACMI being profitable by third quarter 1998. VI. Peter Gombrich has a proven track record. He co-founded St. Jude Medical, Inc. which within the last year had a market cap as high as $3.9 billion. He also founded CliniCom, Inc. which was sold in 1995 for about $60 million. BTW: I understand that the Pathfinder system which Cytyc plans to use is just a simple mapping system. If that is the case, it is much more limited than the total system which AccuMed is putting forth. Cisco